Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
04/2010
04/07/2010CN101690811A Concentrated freeze-dried yolk antibody composite preparation for infectious bursal disease and preparation process thereof
04/06/2010US7691987 Use of a novel eimeria gene and corresponding protein
04/06/2010US7691980 Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
04/06/2010US7691979 Monoclonal antibody named KIS-1N produced by the hybridoma cell line; for development of an agent for the diagnosis and prevention/treatment of diseases (cancer, and so forth) associated with the polypeptide
04/06/2010US7691978 Antibodies that bind TAT294
04/06/2010US7691977 Anti-VEGF antibodies
04/06/2010US7691976 BRAF35 protein and BRCA2/BRAF35 complex and methods of use
04/06/2010US7691973 GFRα3 polypeptides
04/06/2010US7691969 Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same
04/06/2010US7691806 Mixture of protein polymer and active materials
04/06/2010US7691804 Administering formulation selected from a BAFF-R polypeptide or fragment; a chimeric molecule comprising a BAFF-R polypeptide or fragment fused to heterologous amino acid sequence; anti-BAFF-R antibody for inhibiting B-cell growth
04/06/2010US7691632 Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
04/06/2010US7691606 Soluble GDNFR (Glial-cell Derived Neurotrophic Factor) that retains both ligand binding, and receptor signaling function (via Ret receptor tyrosine kinase) used to impart, restore, or enhance GDNFR alpha -ligand (preferably GDNF) responsiveness to cells; kidney diseases
04/06/2010US7691605 Selection of cells expressing heteromeric polypeptides
04/06/2010US7691591 Methods of identifying and isolating cells expressing DC-sign
04/06/2010US7691590 Reducing myelin-mediated inhibition of axon regeneration
04/06/2010US7691588 Ligand having agonistic activity to mutated receptor
04/06/2010US7691586 Method for predicting and judging the recurrence of liver cancer after treating liver cancer
04/06/2010US7691582 Methods of secretory vimentin detection and modulation
04/06/2010US7691568 Antibody composition-containing medicament
04/06/2010US7691567 Fortilin binds p53 and prevents apoptosis; fortilin inhibitor select from the group, polypeptide, an antibody, monoclonal antibody, nucleic acid molecule, antisense molecule or a ribozyme
04/06/2010US7691566 Compositions and methods for treatment of cancer
04/06/2010US7691395 BASB119 polypeptide and polynucleotide from Moraxella catarrhalis
04/06/2010US7691390 polypeptide and isolated nucleic acid encoding the polypeptide for SARS CoV protein 3a, which can serve as a target for elucidating the mechanisms of SARS and developing vaccines and therapeutics
04/06/2010US7691385 Polypeptides encoded by polynucleotides that are useful for detecting resistance to streptogramin A or to streptogramin B and related compounds
04/06/2010US7691380 Coagulating the vascular systems of cancer cells through site specific delivery of coagulant antibodies causing regression of the cells
04/06/2010US7691379 Anti-IL-9 antibody formulations
04/06/2010US7691378 Treating carcinomas or adenocarcinomas using at least one anti-TNF (tumor necrosis factor) antibody
04/06/2010US7691376 monoclonal antibodies or fragment thereof which binds a cell surface glycoprotein antigen located on the surface of human multiple myeloma tumor cells; for therapeutic, screening, diagnostic and cell purification purposes
04/06/2010US7691375 Treating renal clear cell carcinoma; administration of G250-antigen-specific antibodies to high-risk patients diagnosed with non-metastasizing disease; lymphadenectomy
04/06/2010US7691373 Antibody that binds to mammalian Dendritic Cell Membrane Protein (DCMP) genes; immunostimulants
04/06/2010US7691372 contains the idiotype of the HE2 antibody directed against the cellular membrane antigen Ep-CAM
04/06/2010CA2406807C Methods and compositions for the prevention and treatment of anemia
04/06/2010CA2378925C Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
04/06/2010CA2331274C Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
04/06/2010CA2280930C Protein markers for lung cancer and use thereof
04/06/2010CA2252466C Hepatitis b monoclonal antibodies
04/06/2010CA2235393C Therapeutic antiangiogenic endostatin compositions and methods of use
04/06/2010CA2188919C Monoclonal antibodies which promote central nervous system remyelination
04/03/2010CA2640416A1 Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
04/01/2010WO2010037046A1 Humanized neuraminidase antibody and methods of use thereof
04/01/2010WO2010037041A2 Frizzled-binding agents and uses thereof
04/01/2010WO2010037027A2 Immunization of avians by mucosal administration of non-replicating vectored vaccines
04/01/2010WO2010036959A2 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
04/01/2010WO2010036851A2 Single chain antibody library design
04/01/2010WO2010036767A1 High titer antibody production
04/01/2010WO2010036443A1 Cell lines and proteins with variant glycosylation pattern
04/01/2010WO2010036339A2 A method of detecting antibodies and antibody-hiv virion complexes
04/01/2010WO2010036133A1 A method of binding bacterial lipopolysaccharides to a solid phase
04/01/2010WO2010036031A2 Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
04/01/2010WO2010035769A1 Improved antibody molecule
04/01/2010WO2010035465A1 Anti-tuna vasa antibody
04/01/2010WO2010035292A1 The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
04/01/2010WO2010035259A2 Compositions and methods for diagnosing and treating b-cll
04/01/2010WO2010035012A1 Biological products
04/01/2010WO2010034974A2 Tb vaccine
04/01/2010WO2010034956A1 Novel method for non-radioactively measuring protein synthesis and protein marking in living cells
04/01/2010WO2010034825A2 Novel antibodies recognizing native annexin a3
04/01/2010WO2010034812A1 Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis c virus infection
04/01/2010WO2010034718A1 Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
04/01/2010WO2010034700A1 Treating cancer by modulating rna helicases
04/01/2010WO2010034590A1 Composition for treating disease
04/01/2010WO2010034514A2 Cfhr1 as a c5 convertase inhibitor for the treatment of autoimmune diseases
04/01/2010WO2010034443A1 Antibodies against human il 17 and uses thereof
04/01/2010WO2010034441A1 Bispecific anti-egfr/anti-igf-1r antibodies
04/01/2010WO2010034183A1 Human catechol-o-methyltransferase (comt) assay
04/01/2010WO2010034155A1 Kit by detecting egfl7 in samples for the diagnosis of hepatocellular carcinoma and its application
04/01/2010WO2010034103A1 Method for polyclonal immunoglobulin g production by human b cells
04/01/2010WO2010017103A3 Fully human anti-human nkg2d monoclonal antibodies
04/01/2010WO2010003101A3 Il6 immunotherapeutics
04/01/2010WO2009155724A3 Stable and soluble antibodies inhibiting vegf
04/01/2010WO2009155670A3 Pharmaceutical compositions of antibodies for diseases caused by viruses
04/01/2010WO2009150539A3 Variable domains of camelid heavy-chain antibodies directed against androctonus autralis hector toxins
04/01/2010WO2009136976A3 Il-17ra-il-17rb antagonists and uses thereof
04/01/2010WO2009133521A3 Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
04/01/2010WO2009094751A8 An anti-cancer cytotoxic monoclonal antibody
04/01/2010US20100083396 Soybean Gene for Resistance to Aphis glycines
04/01/2010US20100083389 Production of heterologous protein in the avian oviduct
04/01/2010US20100081797 Manipulation of Cytokine Levels Using CD83 Gene Products
04/01/2010US20100081796 Bispecific anti-egfr/anti-igf-1r antibodies
04/01/2010US20100081795 Rg1 antibodies and uses thereof
04/01/2010US20100081794 Modified Glycoproteins and Uses Thereof
04/01/2010US20100081793 Therapeutic uses of humanized antibodies against alpha-4 integrin
04/01/2010US20100081792 Ligand
04/01/2010US20100081709 Isolated snare ykt6 genomic polynucleotide fragments from chomosome 7 and their uses
04/01/2010US20100081212 Antibodies for determining the prothrombin fragment f2/f1+2 in a homogeneous immunoassay
04/01/2010US20100081211 Luminescent lanthanide labelling reagents and their use
04/01/2010US20100081192 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
04/01/2010US20100081147 Human catechol-o-methyltransferase (comt) assay
04/01/2010US20100080854 Atopic dermatitis inducer
04/01/2010US20100080819 Modulators of p-selectin glycoprotein ligand 1
04/01/2010US20100080818 Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
04/01/2010US20100080815 MN Gene and Protein
04/01/2010US20100080814 NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
04/01/2010US20100080813 Neutralizing anti-influenza a virus antibodies and uses thereof
04/01/2010US20100080812 Antibodies against human IL17 and uses thereof
04/01/2010US20100080810 Methods of treating diseases with anti-vegf antibodies
04/01/2010US20100080809 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
04/01/2010US20100080808 Anti-notch2 antibodies and methods of use
04/01/2010US20100080806 Anti-human trail receptor dr5 monoclonal antibody (ad5-10), method thereof and use of the same
1 ... 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 ... 1494